Soliris is named as an intervention in 3 current clinical trials in our China, Germany and France registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Bisirna Therapeutics (Suzhou) Co., Ltd (1). The most-studied condition is Paroxysmal Nocturnal Hemoglobinuria, PNH.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
NCT07010302 · ClinicalTrials.gov ↗ · NMOSD
|
Phase 4 | Recruiting | Massachusetts General Hospital | Germany |
|
Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
NCT05726916 · ClinicalTrials.gov ↗ · Hypertensive Emergency-associated Hemolytic Uremic Syndrome
|
Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | France |
|
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
NCT07816237 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria, PNH
|
Phase 3 | Not yet open | Bisirna Therapeutics (Suzhou) Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Bisirna Therapeutics (Suzhou) Co., Ltd | 1 |
| Massachusetts General Hospital | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in France | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, Germany and France registers name Soliris as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Germany and 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Bisirna Therapeutics (Suzhou) Co., Ltd (1), Massachusetts General Hospital (1) and Assistance Publique - Hôpitaux de Paris (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Soliris works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Soliris works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Soliris (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.